| Name | BTB06584 |
| Description | BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase. BTB06584 is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB). |
| In vitro | BTB06584 restores defective hemoglobin synthesis in zebrafish pinotage (pnt) mutants without evident toxicity. |
| In vivo | BTB06584 inhibits F1Fo-ATPase activity in an IF1-dependent manner, does not affect ATP synthesis, and also restricts ischemia-induced damage caused by the reverse action of mitochondrial F1Fo-ATP synthase. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 78 mg/mL (186.68 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.79 mM), Sonication is recommended.
|
| Keywords | mitochondrial | ischaemic | Inhibitor | inhibit | IF1 | cardioprotective | BTB-06584 | BTB06584 | BTB 06584 | ATPsynthase | ATPase | ATP Synthase | Acetohydroxyacid synthase |
| Inhibitors Related | Losartan potassium | Tranilast | Sodium oleate | Sacubitril/Valsartan | Benzyl benzoate | Irbesartan | 2,3-Butanedione 2-Monoxime | Losartan | Diisononyl phthalate | Captopril | Revaprazan hydrochloride | Oleic acid |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Multi-Target Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Endocrinology-Hormone Compound Library | Mitochondria-Targeted Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Hypertension Compound Library |